Skip to main content
Fast-track status granted to Windtree's istaroxime for acute HFrEF
8/23/2019

Windtree Therapeutics' investigational drug istaroxime, being developed as a potential treatment for acute heart failure with reduced ejection fraction, received fast-track designation from the FDA this month based on results from its Phase IIb trial that showed the drug, injected intravenously, improved cardiac function in patients while also facilitating myocardial relaxation.

Full Story: